Harvard College

American Home Products Corporation

Genetics Institute, Inc.

Tatos Akopian

William Stuart Somers

Rayomand Jal Unwalla

Jonathan A Bard

Mark L Stahl

Alfred L Goldberg

Rajiv Chopra

Chu-Lai Hsiao

Eric J Rubin

Olga Kandror

Kristine Svenson

Meera Unnikrishnan

Zhang-Bao Xu

Ravikiran M Raju

Bethany Annis Freeman

The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.

[object Object]

This invention is directed to the three dimensional crystal structure of Beta-site APP Cleaving Enzyme (BACE), and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of BACE. Such agents may represent new therapeutics in the treatment and/or prevention of Alzheimer's Disease.

Method for identifying agents that interact with beta-site APP cleaving enzyme (BACE)

This invention is directed to the crystal structure of Estrogen Receptor-&#x3b2; (ER-&#x3b2;) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-&#x3b2;, which may be useful as novel chemotherapeutic agents.

Method using crystal structure of estrogen receptor-&#x3b2; complex

Growing community of inventors

West Roxbury, MA, United States of America

Tatos Akopian